VANCOUVER, BC, May 12, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, released its first quarter financial results and operational highlights for the period ended March 31, 2023. “We are pleased to report on another highly productive quarter,” said Benjamin Lightburn…


Previous articlePsychedelics Weekly – Multi-Stakeholder Capitalism, Psilocybin Service Centers Begin Opening in Oregon, and Vancouver’s ‘The Drugs Store’
Next articleatai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)